Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment

Abstract Depression has substantially increased in the last 10 years in Brazil, and mental health became a concerning issue for the public health globally, especially considering the COVID-19 pandemic. The therapeutic conduct in depression mainly relies on medication and psychotherapy. However, more...

Full description

Saved in:
Bibliographic Details
Main Authors: Rafaela Slaviero Pinheiro Cerdeira, Mario Hiroyuki Hirata
Format: Article
Language:English
Published: Universidade de São Paulo 2025-01-01
Series:Brazilian Journal of Pharmaceutical Sciences
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100315&lng=en&tlng=en
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832592536158339072
author Rafaela Slaviero Pinheiro Cerdeira
Mario Hiroyuki Hirata
author_facet Rafaela Slaviero Pinheiro Cerdeira
Mario Hiroyuki Hirata
author_sort Rafaela Slaviero Pinheiro Cerdeira
collection DOAJ
description Abstract Depression has substantially increased in the last 10 years in Brazil, and mental health became a concerning issue for the public health globally, especially considering the COVID-19 pandemic. The therapeutic conduct in depression mainly relies on medication and psychotherapy. However, more than one attempt in the treatment can be considered a common procedure before finding out the right medication. This conduct leads many patients to give up following pharmacological treatment. In this scenario, pharmacogenomics emerges as a possible supporting tool of the medical treatment. This paper aims to analyze the scenario of depression in Brazil and the viability of pharmacogenomic tests implementation as a part of the medical procedure. Official data bank from the Brazilian government was used to analyze the prevalence of depressive disorder, as well as Pharmacogenomic data bases and relevant articles around this topic. Additionally, pharmacogenomic tests typically take into consideration the genes CYP2D6 and CYP2C19, which are relevant for antidepressant treatment. Data shows that these tests could help patients achieve remission of symptoms, and they could also be economically advantageous. Thus, pharmacogenomic tests present as an interesting approach for the therapeutic conduct of depression and can significantly improve the health quality of this affected population.
format Article
id doaj-art-de7158250cde40009ff96b19d63fd47c
institution Kabale University
issn 2175-9790
language English
publishDate 2025-01-01
publisher Universidade de São Paulo
record_format Article
series Brazilian Journal of Pharmaceutical Sciences
spelling doaj-art-de7158250cde40009ff96b19d63fd47c2025-01-21T07:41:09ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902025-01-016110.1590/s2175-97902025e24142Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatmentRafaela Slaviero Pinheiro Cerdeirahttps://orcid.org/0009-0003-0730-2001Mario Hiroyuki Hiratahttps://orcid.org/0000-0002-9521-7979Abstract Depression has substantially increased in the last 10 years in Brazil, and mental health became a concerning issue for the public health globally, especially considering the COVID-19 pandemic. The therapeutic conduct in depression mainly relies on medication and psychotherapy. However, more than one attempt in the treatment can be considered a common procedure before finding out the right medication. This conduct leads many patients to give up following pharmacological treatment. In this scenario, pharmacogenomics emerges as a possible supporting tool of the medical treatment. This paper aims to analyze the scenario of depression in Brazil and the viability of pharmacogenomic tests implementation as a part of the medical procedure. Official data bank from the Brazilian government was used to analyze the prevalence of depressive disorder, as well as Pharmacogenomic data bases and relevant articles around this topic. Additionally, pharmacogenomic tests typically take into consideration the genes CYP2D6 and CYP2C19, which are relevant for antidepressant treatment. Data shows that these tests could help patients achieve remission of symptoms, and they could also be economically advantageous. Thus, pharmacogenomic tests present as an interesting approach for the therapeutic conduct of depression and can significantly improve the health quality of this affected population.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100315&lng=en&tlng=enDepressionPharmacogenomicsPharmacogenomic testing
spellingShingle Rafaela Slaviero Pinheiro Cerdeira
Mario Hiroyuki Hirata
Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
Brazilian Journal of Pharmaceutical Sciences
Depression
Pharmacogenomics
Pharmacogenomic testing
title Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
title_full Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
title_fullStr Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
title_full_unstemmed Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
title_short Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
title_sort analysis of depression in brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
topic Depression
Pharmacogenomics
Pharmacogenomic testing
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100315&lng=en&tlng=en
work_keys_str_mv AT rafaelaslavieropinheirocerdeira analysisofdepressioninbrazilandthefeasibilityofincorporatingpharmacogenomicsasanauxiliarytoolinantidepressanttreatment
AT mariohiroyukihirata analysisofdepressioninbrazilandthefeasibilityofincorporatingpharmacogenomicsasanauxiliarytoolinantidepressanttreatment